Photodynamic therapy (PDT) of malignant tumours using haematoporphyrin derivative (HPD) depends on the selective uptake and retention of HPD in tumours and its subsequent activation by light (Benson, 1985; Forbes et al., 1980; Hayata et al., 1984) . Destruction of tumours is mediated through production of toxic oxygen species by photoactivated HPD (Lee See et al., 1984; Das et al., 1985) .
The primary target of PDT may be the microvasculature of tumours rather than the tumour cells. Studies using radiolabelled HPD indicate that its uptake and retention are greater in the stroma than in the tumour cells and macrophages in this site retain HPD longest (Bugelski et al., 1981) . Tumour blood flow, as measured with microspheres, was reduced after PDT (Selman et al., 1984 (Selman et al., , 1985 and complete cessation of tumour blood flow was observed in rat tumours in observation chambers after PDT (Star et al., 1984) . Histological examination indicated that the primary site of photodynamic damage in the normal mouse brain was the endothelium of small vessels (Berenbaum et al., 1986) . PDT caused necrosis of L1210 solid tumours in mice, but cells isolated from L1210 tumours after the host mice had received HPD contained little HPD and were not killed by irradiation in vitro (Musser & Datta-Gupta, 1984) . Similarly, viability of EMT-6 tumour cells, as measured by capacity to form colonies in vitro, was not reduced if tumours were removed from mice immediately after irradiation in vivo. Viability of cells from tumours left in the mice after irradiation decreased at the same rate as when tumours were made anoxic (Henderson et al., 1985) .
In view of these findings, it could be predicted that vasoactive drugs may modify the outcome of PDT. The uptake of HPD into tumours may be altered by vasodilation or vasoconstriction altering tumour blood flow. The destruction of tumours may also be modified if the drugs sensitise capillaries to photodynamic destruction. The possibility of unwanted side-effects in patients receiving both vasoactive drugs and PDT should also be investigated. Vasodilating drugs propranolol (a beta receptor blocking agent), hydralazine, phenoxybenzamine (an alpha receptor blocking agent) and the vasoconstricting agent noradrenaline were all tested. In addition, the calcium channel blocking agents verapamil, nifedepine and diltiazem, which also have some vasodilating activity, were examined.
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Methods
Mouse tumour assay The assay was modified from Dougherty et al. (1983) (Cowled & Forbes, 1985; Cowled et al., 1985a) . Lewis lung carcinoma cells, cultured in RPMI 1640 supplemented with 10% foetal calf serum (FCS), 2.3mM NaHCO3, 25mM N-2-hydroxyethylpiperazine N'-2-ethanesulphonic acid and 0.16pgml-1 gentamicin, were harvested by treatment with 0.01% trypsin. A total of 106 cells were injected subcutaneously into the back of C57B1 mice. Fresh cultures were established every three months from stock frozen in liquid nitrogen. After 7-10 days, tumours were 5-7mm in diameter and were ready for treatment.
Tumour-bearing mice in groups of 10 were injected with HPD (30mgkg-' i.p.), prepared as in Forbes et al. (1980) . Twenty-four hours later, the mice were anaesthetised with sodium pentobarbitone (Sagatal, May and Baker Australia Proprietary Limited, 60mgkg-1), the fur over the tumour was shaved and the tumours were irradiated over a 1 cm diameter spot with a light dose of 225 J cm-2 from an incandescent lamp (610-680nm) (Jacka & Blake, 1983) . The skin around the tumours was not shielded. Tumours were impalpable 24h after an effective treatment and the endpoint of the assay was the number of days for five of 10 tumours to recur (TC50). There was a linear relationship between the TC50 and both the light and HPD doses (Cowled & Forbes, 1985) . In other experiments, mice were injected with HPD (50mgkg-1), the tumours irradiated 2h later with 225 Jcm-2 light and TC50 determined as described above. All experiments were repeated at least once and means and standard deviations between groups of 10 mice were determined. Differences between groups of mice were analysed by unpaired t tests. Drugs were administered either concurrently with HPD, immediately before irradiation or 24 and 48 h after irradiation. The drug dosages, mode of administration and interval between drug administration and irradiation are described in detail in the figure legends.
In vitro photocytotoxicity Lewis lung carcinoma cells, grown and harvested as described above, were suspended at 107 ml-in RPMI 1640/ 10% FCS and incubated for 1 h at 37°C with 50PCiml-1 5'Cr-sodium chromate (Amersham, Australia). After Br. J. Cancer (1989), 59, 904-909 washing, 51Cr-labelled cells were suspended at 107ml-l in RPMI 1640 without FCS and incubated for 1 h at 37°C with HPD (25 igml-1) and verapamil (0-100 gml-1). The cells were washed once, resuspended in phosphate-buffered saline at 0.5 x 106 ml-1 and irradiated for 0-20min with red light (8mWcm-2). Percentage "Cr release was determined immediately after irradiation as previously described (Cowled et al., 1985b Figure 1 . Slight increases in TC50 observed with noradrenaline and hydralazine were not statistically significant. A significant (P< 0.02) increase in TC50 was observed after 0.5 mg kg-1 propranolol but not after 1.0 mg kg-1. Noradrenaline, propranolol and hydralazine administered immediately before irradiation of tumours in HPD-sensitised mice also had no effect on PDT, the TC50 remaining at 3-4 days in all cases. Drug alone, drug plus HPD, or drug without HPD followed 5 min or 24 h later by irradiation of the tumours did not affect tumours macroscopically. The highest doses of all the drugs tested caused temporary drowsiness in the mice but were not fatal.
Intensity of HPD fluorescence in the tumours was not altered when the vasoactive drugs were administered 24 h before examining fluorescence, indicating that these drugs had no effect on HPD uptake into the tumours. This was in agreement with the lack of influence of the drugs on PDT.
Influence of vasoactive drugs administered 2h before irradiation Since the half-life of the vasoactive drugs in mice could be quite short, examination of the response of the tumours to PDT 24h after drug administration may not reveal shortterm effects. Therefore the interval between administration of HPD plus drug and irradiation was shortened to 2 h. Previous studies had shown 2 h was the shortest interval between HPD and irradiation of the tumours at which an adequate response could be obtained (Cowled, 1986) .
Irradiation 2 h after injection of HPD (50mg kg -1) resulted in a greater TC50 than that observed with an interval of 24h between HPD (30mgkg-1) and light. All the vasoactive drugs which were tested greatly inhibited the tumour response to PDT when the interval between drug and light was 2 h (Figure 2) . Propranolol was the most . inhibitory, appearing to suppress completely the effect of irradiation on some tumours. Fluorescence of tumours was greatly diminished 2h after concurrent administration of HPD (50mgkg-1) and hydralazine (10mlkg-1), propranolol (1mgkg-') or phenoxybenzamine (5mgkg-1), indicating marked inhibition of uptake of HPD. Noradrenaline also inhibited uptake of HPD into the tumours. Fainter fluorescence after 0.2mg kg-1 noradrenaline than O.1 mg kg-was associated with a greater inhibition of efficacy of PDT.
Local administration of noradrenaline (200 il of 0.02mg ml-1, amounting to 0.2mg kg-1 into tumours concurrently with the administration of HPD (50mgkg-1 i.p.) 2h before irradiation, also greatly inhibited the response to PDT. Eight out of 10 tumours were still palpable 24h after irradiation (TC50 of <1 day compared to 8 days). HPD fluorescence in the tumours was also greatly inhibited by local infiltration of noradrenaline. Controls of local noradrenaline alone or noradrenaline plus light had no macroscopic effect on the tumours. These results would indicate that the effect of noradrenaline on uptake of HPD into tumours could be at least partly due to effects of noradrenaline on the tumour blood vessels and not merely due to systemic vasoconstriction affecting the distribution or circulation of HPD in the mouse.
Under the conditions tested, the alpha blocker phenoxybenzamine did not prevent the inhibition of PDT by noradrenaline, an alpha agonist (Figure 2 ). Indeed the inhibition of PDT was enhanced, most tumours being macroscopically unaffected.
Phenoxybenzamine itself administered concurrently with HPD 2h before irradiation, also inhibited PDT (Figure 2 ). The inhibition of PDT by noradrenaline was not altered by concurrent administration of the beta blocker propranolol (Figure 2 ). Higher doses of propranolol in combination with noradrenaline were fatal to the mice. All drugs alone, drugs plus HPD (without irradiation) and drugs plus irradiation (without HPD) had no effect on the rate of tumour growth.
Calcium channel blockers Verapamil (2mgkg-1) potentiated PDT when administered concurrently with HPD 24h before irradiation (Figure 3 ).
No greater effect was seen using this drug at 10mgkg-'. A marked increase in fluorescence in frozen sections 24h after injection of verapamil (10mgkg-1) plus HPD suggested that verapamil increased uptake or retention of HPD in the tumours. A second calcium channel blocking agent, nifedepine, was also tested. Nifedepine, being extremely insoluble in aqueous solutions, was dissolved in 5% dimethyl sulphoxide (DMSO) in saline and then injected concurrently with HPD. Both the photodynamic effect and the uptake of HPD, as assessed by fluorescence, were greatly inhibited. However, 5% DMSO without nifedepine administered with HPD also inhibited both the uptake of HPD and the photodynamic response. The reason for this inhibition is unclear. Thus the influence of nifedepine on PDT could not be assessed. Diltiazem was also tested (Figure 3) . In contrast to verapamil, when diltiazem (10mgkg-1) was administered concurrently with HPD 24h before irradiation, there was no change in the TC50, which remained at 4 days. The fluorescence of HPD in tumours was similarly unaffected by diltiazem. Controls of drugs alone, drug plus HPD or drug plus light had no effect on the tumours.
Verapamil (2mg kg-1) administered 24 and 48 h after irradiation significantly increased the TC50 from 3.6 to 6 days. However, in contrast, neither nifedepine (2 mg kg-1, dissolved in 5% DMSO in saline) or diltiazem (10 or 50mg kg-1) had any effect on the TC50 when administered 24 and 48 h after PDT (Figure 4) (Figure 6 ), suggesting HPD uptake was not affected by verapamil.
Neither verapamil (10-50/jigml-1) alone nor verapamil plus light increased 51Cr release above background. Since incubation of cells in verapamil alone at a concentration of 100 gml-l caused some release of 51Cr above background, higher concentrations of verapamil were not tested. 
Discussion
The influence on PDT of drugs affecting vasculature was examined using a transplantable tumour model in mice. Noradrenaline, propranolol and hydralazine inhibited PDT if given 2h before tumours were irradiated, but had no effect when administered with HPD 24h before irradiation. The fluorescence of HPD in tumours was reduced 2 h after administration of noradrenaline with HPD, but not after 24h. Phenoxybenzamine, an alpha receptor blocking agent and the beta blocker propranolol did not block the inhibitory effect of noradrenaline on PDT. Noradrenaline acts mainly on alpha receptors (Weiner, 1985) . Administration of noradrenaline, hydralazine or propanolol immediately before irradiation had no effect on the TC50.
There is controversy as to whether blood vessels of tumours respond to vasoactive drugs. Blood flow in rat tumours was reduced by local administration of noradrenaline (Mattsson et al., 1980) and vasoconstriction was observed directly by microangiography (Mattsson et al., 1981) . Decreasing vascular responses to propranolol, papaverine and dihydralazine have been observed as tumours age (Wickersham et al., 1977; Peterson & Mattsson, 1984) . As tumours enlarge, the blood vessels become stretched and tortuous, lose adrenergic innervation and show a relative lack of smooth muscle (Mattsson & Peterson, 1981) . The inhibition of PDT by vasolidators administered 2h before irradiation could be explained by dilatation of normal vessels causing diversion of blood from tumours. Reduction of tumour blood flow has been demonstrated after the intravenous doses of noradrenaline used in this study and this effect was blocked by phenoxybenzamine (Mattsson et al., 1978) . However, since phenoxybenzamine itself inhibited PDT, this drug could not be used to block the inhibitory action of noradrenaline on PDT. Administration of these drugs immediately before irradiation had no effect on the response of the tumours to PDT, suggesting that the degree v I 1--
of vasodilation or vasoconstriction of the tumour vasculature at the time of irradiation does not influence the outcome of PDT. Damage to tumours by PDT appears to be mediated by toxic oxygen species, particularly singlet oxygen and hydroxyl radicals (Das et al., 1985) . It is possible that vasoactive drugs alter tumour responses to PDT by altering the oxygen tension in the tumours and hence altering the production of toxic oxygen species. Vasoactive drugs have been reported to alter oxygen tension (Kruuv et al., 1967) .
Verapamil, a calcium channel blocking agent and vasodilator, enhanced the efficacy of PDT. Enhancement of HPD fluorescence in tumours suggested that this resulted from increased uptake of HPD. However, since vasodilators inhibited both uptake of HPD and the degree of photodynamic damage, an effect of verapamil other than its vasodilatory action is probably responsible. The capacity of verapamil to affect blood flow of tumours is also controversial. In one study, tumour blood flow was increased by verapamil without altering blood flow in normal tissues (Kaelin et al., 1982) , but no enhancement of tumour blood flow was detected in another study (Robinson et al., 1985) . It is of interest that verapamil increases the number of low density lipoprotein (LDL) receptors on the surface of cells (Stein et al., 1985) , as it has been suggested that HPD may be taken up into cells by LDL receptors (Candide et al., 1986) .
Verapamil enhances the effect of cytotoxic drugs in other systems. Tumour cell lines, including Lewis lung carcinoma used in this study, resistant to adriamycin and vincristine, were made sensitive by verapamil (Tsuruo et al., 1982 (Tsuruo et al., , 1983a . Intracellular concentrations of cytotoxic drugs were elevated, suggesting that verapamil enhanced uptake or inhibited transport of drugs out of cells. Our studies in vitro did not indicate a direct action of verapamil on the tumour cells. When Lewis lung carcinoma cells were incubated in HPD plus verapamil, HPD fluorescence and 51Cr release were not increased significantly.
The most important effect of verapamil in enhancing PDT appears not to be the enhancement of uptake of HPD into tumours, but prolongation of the tumour-free interval when the drug is administered after irradiation. At least two mechanisms may be suggested to explain this phenomenon:
(1) enhancement of the effect of hypoxia induced by capillary damage after PDT and (2) inhibition of regrowth of the tumour from surviving cells. Since virtually all nonmalignant cells appear to proliferate and differentiate in response to appropriate growth factors, it seems likely that capillaries and host stromal cells may only grow in association with multiplying tumour cells if they also receive the necessary growth factors. Verapamil could inhibit some steps necessary for this process. High-dose cortisone, in combination with heparin, has been shown to inhibit angiogenesis (Folkman et al., 1983; Crum et al., 1985) . Glucocorticoids administered after PDT also inhibit recurrence of tumours (Cowled et al., 1985a) . It is also of interest that the effects on PDT of verapamil are not common to all calcium channel blocking drugs and the reasons for these differences are not known. Diltiazem, a drug with pharmacological action similar to that of verapamil (Needleman et al., 1985) , had no effect on the uptake of HPD. Diltiazem and nifedepine also had no effect on the rate of recurrence of tumours after PDT. We conclude that many vasoactive drugs may modify the uptake of HPD, inhibiting PDT if tumours are irradiated shortly afterwards. Verapamil acts differently, both enhancing the uptake of HPD and acting after photodynamic destruction to inhibit the regrowth of tumours. Verapamil may be very useful clinically to enhance the efficacy of PDT and experimentally to study the regrowth of tumours after PDT.
